Search

Displaying results 5201 - 5210 of 10000 in total
  1. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  2. Drug

    Rufloxacin

    go.drugbank.com/drugs/DB13772
    Investigational

    Rufloxacin is a quinolone antibiotic.[A31894]

    Categories: Topoisomerase II Inhibitors
  3. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  4. Drug

    Posizolid

    go.drugbank.com/drugs/DB04850
    Investigational

    In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though … Posizolid (AZD2563) is an oxazolidinone antibiotic.

  5. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.

  6. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  7. Drug

    Dapansutrile

    go.drugbank.com/drugs/DB16130
    Investigational

    Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

  8. Drug

    Cefapirin

    go.drugbank.com/drugs/DB01139
    ApprovedVet approved

    Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms. … Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations.

  9. Drug

    Methyl undecenoyl leucinate

    go.drugbank.com/drugs/DB11272
    Approved

    Methyl undecenoyl leucinate is an active ingredient in whitening creams. … It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.

  10. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary … [A244705, A244710, A244745] Gantenerumab is a fully human IgG1κ monoclonal antibody derived from the MorphoSys HuCAL®-Fab1 phage display library and subsequently optimized by _in vitro_ CDR cassette